U.S. markets open in 6 hours 44 minutes
  • S&P Futures

    4,340.50
    -63.25 (-1.44%)
     
  • Dow Futures

    33,921.00
    -332.00 (-0.97%)
     
  • Nasdaq Futures

    14,206.50
    -294.50 (-2.03%)
     
  • Russell 2000 Futures

    2,007.10
    -24.60 (-1.21%)
     
  • Crude Oil

    83.71
    +0.40 (+0.48%)
     
  • Gold

    1,842.00
    +0.30 (+0.02%)
     
  • Silver

    23.82
    +0.02 (+0.08%)
     
  • EUR/USD

    1.1312
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    1.7350
    0.0000 (0.00%)
     
  • Vix

    29.90
    +1.05 (+3.64%)
     
  • GBP/USD

    1.3474
    -0.0017 (-0.12%)
     
  • USD/JPY

    113.8090
    -0.1510 (-0.13%)
     
  • BTC-USD

    36,023.01
    +866.07 (+2.46%)
     
  • CMC Crypto 200

    818.08
    +7.47 (+0.92%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,131.34
    -457.03 (-1.66%)
     

Better Buy: Vertex Pharmaceuticals vs. CRISPR

·5 min read
Better Buy: Vertex Pharmaceuticals vs. CRISPR
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • VRTX
  • CRSP

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) each have their own strengths. Vertex has developed a blockbuster portfolio of cystic fibrosis (CF) treatments. CRISPR is working on gene-editing treatments for a variety of serious diseases.